• Servier agreed to buy Edgewise Therapeutics’ muscular dystrophy business for up to USD 2.65 billion.
• Deal includes USD 1.55 billion upfront, with up to USD 1.1 billion tied to regulatory and commercial milestones.
• Assets include sevasemten, a late-stage oral fast skeletal myosin inhibitor studied in Becker muscular dystrophy, with Phase 2 work in Duchenne.
• Servier expects the transaction to close in the third quarter of 2026, subject to customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606010830PR_NEWS_USPR_____LN72327) on June 01, 2026, and is solely responsible for the information contained therein.